Disease‐modifying drug therapies

References

• Brooks BR, Juhasz-Poscine K, Waclawik A et al. Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: beta-2 adrenergic agonists. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 1 (Suppl 4) 2000; 45–53; discussion 53–54.
   Google Scholar
• Carter GT, Krivickas LS, Weydt P, Weiss MD, Miller RG. Drug therapy for amyotrophic lateral sclerosis: where are we now? Drugs 2003; 6(2): 147–153.
   Google Scholar
• Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V, Riluzole/ALS Study Group II. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. Journal of Neurology 2002; 249(5): 609–615.
   Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. New England Journal of Medicine 1994; 330(9): 585–591.
   Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347(9013): 1425–1431.
   Google Scholar
• Miller RG, Bouchard JP, Duquette P et al. Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group-II. Neurology 1996; 47(Suppl 2): S86–90; discussion S90–92.
   Google Scholar
• Dunlop J, Beal F, McIIvain H, She Y, Howland DS. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. Journal of Neuroscience 2003; 23(5): 1688–1696.
   Google Scholar
• Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Archives of Neurology 1998; 55(4): 526–528.
   Google Scholar
• Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole- tocopherol Study Group. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2001; 2(1): 9–18.
   Google Scholar
• Debove C, Zeisser P, Salzman PM, Powe LK, Truffinet P. The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2001; 2(3): 153–158.
   Google Scholar
• Lacomblez L, Bensimon G, Leigh PN et al. and the ALS Study Groups I and II. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2002; 3(1): 23–29.
   Google Scholar
• Meininger V, Dib M, Aubin F, Jourdain G, Zeisser P. The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS/Riluzole Study Group III. Journal of Neurology 1997; 244 (Suppl 2): S22–25.
   Google Scholar
• Pongratz D, Neundorfer B, Fischer W. German open label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS). Journal of the Neurological Sciences 2000; 180(1–2): 82–85.
   Google Scholar
• Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis: a population-based study in Ireland, 1996–2000. Journal of Neurology 2003; 250(4): 473–479.
   Google Scholar
• Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyo- trophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2002; 3(1): 15–21.
   Google Scholar
• Miller RG, Anderson FA Jr, Bradley WG et al. The ALS patient care database: goals, design, and early results. ALS CARE Study Group. Neurology 2000; 54(1): 53–57.
   Google Scholar
• Barnett D. Riluzole for motor neuron disease. Reply from chairman of appraisal committee at NICE. Br Med J 2001; 323(7312): 573.
   Google Scholar
• Bryan S, Barton P, Burls A. The clinical effectiveness and cost- effectiveness of riluzole for motor neuron disease: an update. National Institute for Clinical Excellence Health Technology Assessment Report Part 2, 2001; pp. 1–6. http://www.nice.org. uk/pdf/Riluzole/htarep/part2.pdf
   Google Scholar
• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Systematic Reviews 2000; (2): CD001447.
   Google Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Systematic Reviews 2001; (2): CD001447.
   Google Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Systematic Reviews 2002; (2): CD001447.
   Google Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2003; 4(3): 191–206.
   Google Scholar
• Sandercock J, Burls A, Hyde C et al. Riluzole for motor neuron disease: more trials are needed. Br Med J 2001; 322(7297): 1305.
   Google Scholar
• Stewart A, Sandercock J, Bryan S, Hyde C, Fry-Smith A, Burls A. The clinical effectiveness and cost-effectiveness of riluzole for motor neuron disease: an update. National Institute for Clinical Excellence Health Technology Assessment Report Part 1, 2000. pp. 1–75. http://www.nice.org.uk/pdf/Riluzole/htarep/part1.pdf
   Google Scholar
• Stewart R. Riluzole for motor neuron disease: ambiguous diagnostic criteria mean that wide variations in eligibility may still persist. Br Med J 2001; 322(7297): 1305–1306.
   Google Scholar
• Wheatley K, Gray R. Riluzole for motor neuron disease. Large, more economical trial is needed. Br Med J 2001; 322(7297): 1305.
   Google Scholar
• Stewart A, Sandercock J, Bryan S et al. The clinical effectiveness and cost-effectiveness of riluzole for motor neuron disease: a rapid and systematic review. Executive Summary. Health Technology Assessment 2001; 5(2): 1–4. www.ncchta.org/ pdfexecs/summ502.pdf
   Google Scholar
• Massof RW, Finklestein D. A two-stage hypothesis for the natural course of retinitis pigmentosa. In Zrenner E, Krastel H, Goebel H (Eds). Research in Retinitis Pigmentosa. Advances in the Biosciences 1987; 62: 29–58.
   Google Scholar